Kenvue Inc. $KVUE Shares Sold by DAVENPORT & Co LLC

DAVENPORT & Co LLC reduced its position in Kenvue Inc. (NYSE:KVUE) by 80.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 39,838 shares of the company’s stock after selling 165,769 shares during the period. DAVENPORT & Co LLC’s holdings in Kenvue were worth $687,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new stake in shares of Kenvue during the third quarter worth $25,000. NBT Bank N A NY increased its stake in Kenvue by 180.3% in the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the last quarter. Cornerstone Planning Group LLC lifted its position in Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the period. Golden State Wealth Management LLC lifted its position in Kenvue by 150.1% during the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after buying an additional 1,190 shares during the period. Finally, Trust Co. of Vermont boosted its stake in Kenvue by 50.9% in the 3rd quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE KVUE opened at $17.22 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The firm has a market capitalization of $33.00 billion, a P/E ratio of 22.36, a P/E/G ratio of 3.98 and a beta of 0.51. The business’s 50-day simple moving average is $18.01 and its 200-day simple moving average is $17.11.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The firm had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same quarter in the prior year, the company earned $0.26 EPS. The company’s revenue was up 3.2% on a year-over-year basis. Equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is presently 107.79%.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent analyst reports. Citigroup lifted their price target on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, February 18th. Canaccord Genuity Group raised their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. UBS Group boosted their target price on shares of Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a report on Wednesday, February 18th. Barclays upped their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Friday, March 6th. Finally, Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $23.00 to $18.00 in a report on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $19.58.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.